FIELD: pharmaceutics.
SUBSTANCE: invention relates to prodrugs of opioid active substance, which provide controlled release of active substance by enzymatic decomposition with further intramolecular cyclization. Invention also relates to compositions, containing prodrugs, and methods for using them.
EFFECT: composition can optionally include trypsin inhibitor, which interacts with enzyme, which is mediator in release of active substance from prodrugs in order to attenuate enzymatic splitting of prodrug.
16 cl, 17 dwg, 15 tbl, 49 ex
| Title | Year | Author | Number |
|---|---|---|---|
| COMPOSITIONS COMPRISING ENZYME-CLEAVABLE KETONE-MODIFIED OPIOID PRODRUGS AND OPTIONAL INHIBITORS THEREOF | 2010 |
|
RU2600736C2 |
| COMBINED THERAPY INCLUDING SGLT INHIBITORS AND DPP4 INHIBITORS | 2009 |
|
RU2481106C2 |
| SOME CHEMICAL STRUCTURES, COMPOSITIONS AND METHODS | 2009 |
|
RU2513636C2 |
| SUBSTITUTED QUINOLINE DERIVATIVES AS MITOTIC KINESIN INHIBITORS | 2005 |
|
RU2385867C2 |
| TREATMENT AND PREVENTION OF RESTLESS LEG SYNDROME WITH USING GABA ANALOGUE PRODRUGS | 2004 |
|
RU2458049C2 |
| TREATMENT OR PREVENTION OF RESTLESS LEGS SYNDROME WITH USING PROMEDICINES OF GABA ANALOGUES | 2004 |
|
RU2377234C2 |
| PHARMACEUTICAL COMPOSITIONS WITH REDUCED RELEASE OF PHENOL OPIOIDS | 2009 |
|
RU2562583C2 |
| INHIBITORS OF TH2-DIFFERENTIATION | 2000 |
|
RU2230551C2 |
| COMBINATION OF HDA INHIBITOR AND ANTIMETABOLITE | 2007 |
|
RU2469717C2 |
| APPLICATION OF HDAC INHIBITORS FOR TREATING MYELOMA | 2006 |
|
RU2420279C2 |
